Four pricing structures separate an advertised GLP-1 figure from what lands on your card
Membership fees outside the headline, dose tiers, introductory rates and prepay-only pricing. They stack, and all four are visible if you ask four questions.
An advertised monthly figure in this market is frequently the medication at a starting dose, on a twelve-month prepay, excluding a membership fee. Each of those is disclosed somewhere. None of them is comparable to a flat all-in figure.
The dose tier matters most. Every published efficacy figure was collected at a maintenance dose, so a price quoted at a starting dose describes a point in treatment no trial measured an outcome at.
One question collapses all four: what is the all-in monthly total at a maintenance dose? Full breakdown: the advertised price is not the price.
Filed by the Peptides Editorial research desk. Corrections: the corrections log.